VAERS Explorer
Back to explore

Report #2864176

Received Oct 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
FL
Recovered
Unknown
Vaccinated
Nov 8, 2024
Onset
Nov 8, 2024
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
IPVPOLIO VIRUS, INACT. (IPOL)SANOFI PASTEURUNK—OT

Symptoms (2)

Incomplete course of vaccinationNo adverse event

Symptom narrative

it was determined that the patient's vaccination status for polio was incomplete and that the patient was required to get additional doses for it with no adverse event; Initial information received on 02-Oct-2025 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves Adult male patient who was administered with IPV (VERO) [IPOL] and it was determined that the patient's vaccination status was incomplete and he was required to get additional doses for it with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 08-Nov-2024, the patient received 0.5 ml dose of suspect Ipv (Vero), Suspension for injection (lot number and expiry date not reported) strength: standard, frequency: once, via intramuscular route in the deltoid nos (Not otherwise specified) for Immunization, it was determined that the patient's vaccination status was incomplete and he was required to get additional doses for it with no adverse event (incomplete course of vaccination) (latency: same day). Information on the batch number was requested corresponding to the one at time of event occurrence. Reportedly, pharmacist said that the patient was under the impression that they only needed one dose. Pharmacist was unsure if left or right Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.